查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1552620

萤光原位杂合反应成像系统市场规模、份额、趋势分析报告：按产品、应用、最终用途、地区和细分市场预测，2024-2030 年

Fluorescence In Situ Hybridization Imaging Systems Market Size, Share & Trends Analysis Report By Product (Instruments), By Application (Cancer Diagnosis), By End Use, By Region, And Segment Forecasts, 2024 - 2030
出版日期: | 出版商: Grand View Research | 英文 120 Pages | 商品交期: 2-10个工作天内

价格
简介目录

萤光原位杂合反应成像系统市场成长与趋势：

Grand View Research, Inc.最新报告显示，预计2030年全球萤光杂合反应成像系统市场规模将达21.4亿美元，2024年至2030年复合年增长率为8.4%。

与体外诊断相关的研发投资的增加预计将推动萤光原位杂合反应（FISH）成像系统市场的发展。欧洲诊断製造商协会等政府机构的存在也对成长做出了贡献，该协会专注于开拓和发展欧洲体外诊断市场。

此外，FISH 成像系统在诊断领域越来越受欢迎，以确定疑似由病原体和细菌引起的疾病。淋巴瘤、固态肿瘤、白血病、自闭症和其他发育综合症等遗传性疾病发病率的增加预计也将推动采用。萤光检查设备、显微镜、照明器和 CCD 相机在传染病检查中变得越来越常见，这些系统的成长机会正在扩大。预计该市场将受到与染色体异常相关的疾病（例如癌症和遗传异常）日益流行以及开发中国家未满足的诊断和临床需求的推动。

此外，对快速、灵敏和准确的疾病检验诊断技术的需求不断增加，意识不断提高，医疗保健支出不断增加，以及开发新型成像系统的广泛研究和开发也将推动预测期内的增长。

萤光杂合反应成像系统市场报告亮点

  • FISH 成像服务预计在预测期内将以最快的速度成长。
  • 目前，FISH成像在癌症诊断的市场渗透率非常高，因此诊断实验室部门占了较大的收益。
  • 由于癌症发生率不断上升，癌症诊断占据了最大的收益占有率，刺激了 FISH 影像系统的采用。
  • 在最终用途领域，伴同性诊断预计将比研究和诊断成长更快。
  • 这些系统主要用于各种临床研究，包括子宫颈癌癌前病变的可视化、人类乳突病毒风险评估、白血病、骨髓发育不良症候群、多发性骨髓瘤和染色体异常的检测，因此诊断实验室占据了主导地位。
  • 由于这些解决方案在该地区的研发中广泛采用，北美地区占据了最大的收益占有率。
  • 由于製造商和政府的投资增加、政府在生物技术领域的积极倡议以及大量开拓机会的存在，预计亚太地区在预测期内将呈现良好的复合年增长率。
  • 该行业竞争激烈，少数玩家占了整体收益的大部分。一些最着名的市场参与企业包括 Euroclone SpA、TissueGnostics GmbH、安捷伦科技公司、Abnova 台湾公司、BioGenex Laboratories Inc.、o Bio-View Ltd. 和通用电气公司。这些在该行业中占据了很大的份额。

目录

第一章调查方法和范围

第 2 章执行摘要

第 3 章萤光原位杂合反应成像系统的变数、趋势和范围

  • 市场介绍/系统展望
  • 市场规模及成长前景
  • 市场动态
    • 市场驱动因素分析
    • 市场限制因素分析
  • 萤光原位杂合反应成像系统分析工具
    • 波特的分析
    • PESTEL分析

第四章萤光杂合反应成像系统市场：依产品估计和趋势分析

  • 细分仪表板
  • 萤光原位杂合反应成像系统市场：2023 年和 2030 年产品变化分析
  • 装置
  • 耗材及配件
  • 服务
  • 软体

第5章萤光杂合反应成像系统：应用估计与趋势分析

  • 细分仪表板
  • 萤光原位杂合反应成像系统市场：2023 年和 2030 年应用变化分析
  • 癌症诊断
    • 2018-2030 年市场收益估计与预测
    • 肺癌
    • 乳癌
    • 其他的
  • 遗传性疾病的诊断
    • 2018-2030 年市场收益估计与预测
  • 其他的
    • 2018-2030 年市场收益估计与预测

第 6 章萤光原位杂合反应成像系统：依最终用途进行估算与趋势分析

  • 细分仪表板
  • 萤光原位杂合反应成像系统市场：2023 年和 2030 年最终用途变化分析
  • 诊断实验室
    • 2018-2030 年市场收益估计与预测
  • 研究/学术机构
    • 2018-2030 年市场收益估计与预测
  • 其他的
    • 2018-2030 年市场收益估计与预测

第7章萤光杂合反应成像系统市场：区域估计与趋势分析

  • 2023 年和 2030 年萤光原位杂合反应成像系统按地区份额
  • 北美洲
    • 北美萤光原位杂合反应影像系统估算与预测，2018-2030
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 2018-2030年欧洲萤光原位杂合反应成像系统的估算与预测
    • 英国
    • 德国
    • 法国
    • 义大利
    • 西班牙
    • 丹麦
    • 瑞典
    • 挪威
  • 亚太地区
    • 2018-2030年亚太地区萤光原位杂合反应成像系统的估算与预测
    • 日本
    • 中国
    • 印度
    • 韩国
    • 泰国
  • 拉丁美洲
    • 拉丁美洲萤光原位杂合反应成像系统的估计和预测，2018-2030
    • 巴西
    • 阿根廷
  • 中东和非洲
    • 2018-2030 年中东和非洲萤光杂合反应成像系统的估算和预测
    • 南非
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 科威特

第八章 竞争格局

  • 主要市场参与企业的最新趋势和影响分析
  • 公司分类
  • 企业热力图分析
  • 公司简介
    • Euroclone SpA
    • TissueGnostics GmbH
    • Agilent Technologies, Inc.
    • Abnova Taiwan Corp
    • BioGenex Laboratories Inc
    • Leica Biosystems Nussloch GmbH
    • Bio-View Ltd
    • Thermo Fisher Scientific, Inc.
    • MetaSystems Probes GmbH
简介目录
Product Code: GVR-1-68038-653-0

Fluorescence In Situ Hybridization Imaging Systems Market Growth & Trends:

The global fluorescence in situ hybridization imaging systems market size is expected to reach USD 2.14 billion by 2030, expanding at a CAGR of 8.4% from 2024 to 2030, according to a new report by Grand View Research, Inc. Increasing R&D investments pertaining to in vitro diagnostics are expected to drive the Fluorescence In Situ Hybridization (FISH) imaging systems market. The presence of government organizations, such as the European Diagnostic Manufacturers Association that focuses on the development and growth of the in vitro diagnostics market in Europe, is also contributing to growth.

Furthermore, FISH imaging systems are gaining popularity in diagnostics for the determination of suspected diseases caused by pathogens or bacteria. Increasing incidence of genetic diseases, such as lymphoma, solid tumors, leukemia, autism, and other developmental syndromes, is also expected to boost adoption. Growing penetration of fluoroscopy, microscopes, illuminators, and CCD cameras in testing for infectious diseases is expanding growth opportunities for these systems. Increasing prevalence of diseases with chromosomal aberrations, such as cancer and genetic abnormalities, as well as unmet diagnostic & clinical needs in developing countries, is anticipated to drive the market.

Moreover, increasing demand for rapid, sensitive, & accurate diagnostic techniques for validation of diseases, coupled with rising awareness, increase in healthcare expenditure, and extensive R&D for the development of novel imaging systems are also expected to drive growth over the forecast period.

Fluorescence In Situ Hybridization Imaging Systems Market Report Highlights:

  • Instruments held the largest market, whereas FISH imaging services are expected to grow at the fastest rate during the forecast period
  • At present, the market penetration of FISH imaging in cancer diagnostics is very high, hence the diagnostic laboratories segment accounted for larger revenues
  • Cancer diagnosis held the largest revenue share owing to increasing incidence of cancer, thus fueling the adoption of FISH imaging systems
  • Among end-use segments, companion diagnostics is expected to witness faster growth than research and diagnostic segments
  • Diagnostic laboratories held the dominant position in 2016 as these systems are predominantly used in various clinical studies for visualization of precancerous lesions in cervical cancer, assessing the risk of human papillomavirus, and for detection of leukemia, myelodysplastic syndrome, multiple myeloma, & chromosomal abnormalities
  • North America held the largest revenue share owing to extensive adoption of these solutions in research and development across this region
  • Asia Pacific is anticipated to exhibit lucrative CAGR over the forecast period due to the increase in investments by manufacturers & governments, supportive government initiatives in the biotechnology sector, and the presence of a large number of untapped opportunities
  • The industry is highly competitive with a limited number of players holding a majority of the overall revenues. Some of the most notable market participants are Euroclone SpA, TissueGnostics GmbH, Agilent Technologies, Inc., Abnova Taiwan Corp, BioGenex Laboratories Inc., o Bio-View Ltd and General Electric Company. They account for a considerable share of the industry

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation and Scope
  • 1.2. Market Definitions
  • 1.3. Research Methodology
    • 1.3.1. Information Procurement
    • 1.3.2. Information or Data Analysis
    • 1.3.3. Market Formulation & Data Visualization
    • 1.3.4. Data Validation & Publishing
  • 1.4. Research Scope and Assumptions
    • 1.4.1. List of Data Sources

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
  • 2.3. Competitive Insights

Chapter 3. Fluorescence In Situ Hybridization Imaging Systems Variables, Trends, & Scope

  • 3.1. Market Introduction/Lineage Outlook
  • 3.2. Market Size and Growth Prospects (USD Million)
  • 3.3. Market Dynamics
    • 3.3.1. Market Drivers Analysis
    • 3.3.2. Market Restraints Analysis
  • 3.4. Fluorescence In Situ Hybridization Imaging Systems Analysis Tools
    • 3.4.1. Porter's Analysis
      • 3.4.1.1. Bargaining power of the suppliers
      • 3.4.1.2. Bargaining power of the buyers
      • 3.4.1.3. Threats of substitution
      • 3.4.1.4. Threats from new entrants
      • 3.4.1.5. Competitive rivalry
    • 3.4.2. PESTEL Analysis
      • 3.4.2.1. Political landscape
      • 3.4.2.2. Economic and Social landscape
      • 3.4.2.3. Technological landscape
      • 3.4.2.4. Environmental landscape
      • 3.4.2.5. Legal landscape

Chapter 4. Fluorescence In Situ Hybridization Imaging Systems Market: Product Estimates & Trend Analysis

  • 4.1. Segment Dashboard
  • 4.2. Fluorescence In Situ Hybridization Imaging Systems Market: Product Movement Analysis, 2023 & 2030 (USD Million)
  • 4.3. Instruments
    • 4.3.1. Instruments Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 4.3.2. Microscopes
      • 4.3.2.1. Microscopes Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 4.3.3. Automated cell analyzers
      • 4.3.3.1. Instruments Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 4.3.4. Others
      • 4.3.4.1. Instruments Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.4. Consumables & Accessories
    • 4.4.1. Consumables & Accessories Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.5. Services
    • 4.5.1. Services Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.6. Software
    • 4.6.1. Software Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 5. Fluorescence In Situ Hybridization Imaging Systems: Application Estimates & Trend Analysis

  • 5.1. Segment Dashboard
  • 5.2. Fluorescence In Situ Hybridization Imaging Systems Market: Application Movement Analysis, 2023 & 2030 (USD Million)
  • 5.3. Cancer Diagnosis
    • 5.3.1. Cancer Diagnosis Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 5.3.2. Lung Cancer
      • 5.3.2.1. Lung Cancer Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 5.3.3. Breast Cancer
      • 5.3.3.1. Breast Cancer Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 5.3.4. Others
      • 5.3.4.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.4. Genetic Disease Diagnosis
    • 5.4.1. Genetic Disease Diagnosis Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.5. Others
    • 5.5.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 6. Fluorescence In Situ Hybridization Imaging Systems: End Use Estimates & Trend Analysis

  • 6.1. Segment Dashboard
  • 6.2. Fluorescence In Situ Hybridization Imaging Systems Market: End Use Movement Analysis, 2023 & 2030 (USD Million)
  • 6.3. Diagnostic Laboratories
    • 6.3.1. Diagnostic Laboratories Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.4. Research & Academic Institutes
    • 6.4.1. Research & Academic Institutes Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.5. Others
    • 6.5.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 7. Fluorescence In Situ Hybridization Imaging Systems Market: Regional Estimates & Trend Analysis

  • 7.1. Fluorescence In Situ Hybridization Imaging Systems Share, By Region, 2023 & 2030 (USD Million)
  • 7.2. North America
    • 7.2.1. North America Fluorescence In Situ Hybridization Imaging Systems Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.2.2. U.S.
      • 7.2.2.1. U.S. Fluorescence In Situ Hybridization Imaging Systems Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.2.3. Canada
      • 7.2.3.1. Canada Fluorescence In Situ Hybridization Imaging Systems Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.2.4. Mexico
      • 7.2.4.1. Mexico Fluorescence In Situ Hybridization Imaging Systems Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.3. Europe
    • 7.3.1. Europe Fluorescence In Situ Hybridization Imaging Systems Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.2. U.K.
      • 7.3.2.1. U.K. Fluorescence In Situ Hybridization Imaging Systems Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.3. Germany
      • 7.3.3.1. Germany Fluorescence In Situ Hybridization Imaging Systems Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.4. France
      • 7.3.4.1. France Fluorescence In Situ Hybridization Imaging Systems Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.5. Italy
      • 7.3.5.1. Italy Fluorescence In Situ Hybridization Imaging Systems Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.6. Spain
      • 7.3.6.1. Spain Fluorescence In Situ Hybridization Imaging Systems Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.7. Denmark
      • 7.3.7.1. Denmark Fluorescence In Situ Hybridization Imaging Systems Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.8. Sweden
      • 7.3.8.1. Sweden Fluorescence In Situ Hybridization Imaging Systems Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.9. Norway
      • 7.3.9.1. Sweden Fluorescence In Situ Hybridization Imaging Systems Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.4. Asia Pacific
    • 7.4.1. Asia Pacific Fluorescence In Situ Hybridization Imaging Systems Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.2. Japan
      • 7.4.2.1. Japan Fluorescence In Situ Hybridization Imaging Systems Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.3. China
      • 7.4.3.1. China Fluorescence In Situ Hybridization Imaging Systems Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.4. India
      • 7.4.4.1. India Fluorescence In Situ Hybridization Imaging Systems Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.5. South Korea
      • 7.4.5.1. South Korea Fluorescence In Situ Hybridization Imaging Systems Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.6. Thailand
      • 7.4.6.1. Thailand Fluorescence In Situ Hybridization Imaging Systems Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.5. Latin America
    • 7.5.1. Latin America Fluorescence In Situ Hybridization Imaging Systems Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.5.2. Brazil
      • 7.5.2.1. Brazil Fluorescence In Situ Hybridization Imaging Systems Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.5.3. Argentina
      • 7.5.3.1. Argentina Fluorescence In Situ Hybridization Imaging Systems Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.6. Middle East and Africa
    • 7.6.1. Middle East and Africa Fluorescence In Situ Hybridization Imaging Systems Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.6.2. South Africa
      • 7.6.2.1. South Africa Fluorescence In Situ Hybridization Imaging Systems Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.6.3. Saudi Arabia
      • 7.6.3.1. Saudi Arabia Fluorescence In Situ Hybridization Imaging Systems and Forecasts, 2018 - 2030 (USD Million)
    • 7.6.4. UAE
      • 7.6.4.1. Fluorescence In Situ Hybridization Imaging Systems Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.6.5. Kuwait
      • 7.6.5.1. Kuwait Fluorescence In Situ Hybridization Imaging Systems Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Recent Developments & Impact Analysis by Key Market Participants
  • 8.2. Company Categorization
  • 8.3. Company Heat Map Analysis
  • 8.4. Company Profiles
    • 8.4.1. Euroclone SpA
      • 8.4.1.1. Participant's Overview
      • 8.4.1.2. Financial Performance
      • 8.4.1.3. Product Benchmarking
      • 8.4.1.4. Recent Developments/ Strategic Initiatives
    • 8.4.2. TissueGnostics GmbH
      • 8.4.2.1. Participant's Overview
      • 8.4.2.2. Financial Performance
      • 8.4.2.3. Product Benchmarking
      • 8.4.2.4. Recent Developments/ Strategic Initiatives
    • 8.4.3. Agilent Technologies, Inc.
      • 8.4.3.1. Participant's Overview
      • 8.4.3.2. Financial Performance
      • 8.4.3.3. Product Benchmarking
      • 8.4.3.4. Recent Developments/ Strategic Initiatives
    • 8.4.4. Abnova Taiwan Corp
      • 8.4.4.1. Participant's Overview
      • 8.4.4.2. Financial Performance
      • 8.4.4.3. Product Benchmarking
      • 8.4.4.4. Recent Developments/ Strategic Initiatives
    • 8.4.5. BioGenex Laboratories Inc
      • 8.4.5.1. Participant's Overview
      • 8.4.5.2. Financial Performance
      • 8.4.5.3. Product Benchmarking
      • 8.4.5.4. Recent Developments/ Strategic Initiatives
    • 8.4.6. Leica Biosystems Nussloch GmbH
      • 8.4.6.1. Participant's Overview
      • 8.4.6.2. Financial Performance
      • 8.4.6.3. Product Benchmarking
      • 8.4.6.4. Recent Developments/ Strategic Initiatives
    • 8.4.7. Bio-View Ltd
      • 8.4.7.1. Participant's Overview
      • 8.4.7.2. Financial Performance
      • 8.4.7.3. Product Benchmarking
      • 8.4.7.4. Recent Developments/ Strategic Initiatives
    • 8.4.8. Thermo Fisher Scientific, Inc.
      • 8.4.8.1. Participant's Overview
      • 8.4.8.2. Financial Performance
      • 8.4.8.3. Product Benchmarking
      • 8.4.8.4. Recent Developments/ Strategic Initiatives
    • 8.4.9. MetaSystems Probes GmbH
      • 8.4.9.1. Participant's Overview
      • 8.4.9.2. Financial Performance
      • 8.4.9.3. Product Benchmarking
      • 8.4.9.4. Recent Developments/ Strategic Initiatives